+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development

An overall picture of SARS coronavirus (SARS-CoV) genome-encoded major proteins: structures, functions and drug development

Current Pharmaceutical Design 12(35): 4539-4553

A severe atypical pneumonia designated as severe acute respiratory syndrome (SARS) by The World Health Organization broke out in China and menaced to more than other 30 countries between the end of the year 2002 and June of the year 2003. A novel coronavirus called severe acute respiratory syndrome coronavirus (SARS-CoV) has been recently identified as the etiological agent responsible for the infectious SARS disease. Based on extensively scientific cooperation and almost two-year's studies, remarkable achievements have been made in the understanding of the phylogenetic property and the genome organization of SARS-CoV, as well as the detailed characters of the major proteins involved in SARS-CoV life cycle. In this review, we would like to summarize the substantial scientific progress that has been made towards the structural and functional aspects of SARS-CoV associated key proteins. The progress focused on the corresponding key proteins' structure-based drug and vaccine developments has been also highlighted. The concerted and cooperative response for the treatment of the SARS disease has been proved to be a triumph of global public health and provides a new paradigm for the detection and control of future emerging infectious disease threats.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 048241395

Download citation: RISBibTeXText

PMID: 17168760

Related references

An Overall Picture of Sars Coronavirus (Sars-CoV) Genome-Encoded Major Proteins: Structures, Functions and Drug Development. Current Pharmaceutical Design 12(35): 4539-4553, 2006

Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Research 65(2): 69-78, 2005

Development and evaluation of an efficient 3'-noncoding region based SARS coronavirus (SARS-CoV) RT-PCR assay for detection of SARS-CoV infections. Journal of Virological Methods 120(1): 33-40, 2004

Differential sensitivities of severe acute respiratory syndrome (SARS) coronavirus spike polypeptide enzyme-linked immunosorbent assay (ELISA) and SARS coronavirus nucleocapsid protein ELISA for serodiagnosis of SARS coronavirus pneumonia. Journal of Clinical Microbiology 43(7): 3054-3058, 2005

Development of a quantitative assay for SARS coronavirus and correlation of GAPDH mRNA with SARS coronavirus in clinical specimens. Journal of Clinical Pathology 58(3): 276-280, 2005

Immunogenicity difference between the SARS coronavirus and the bat SARS-like coronavirus spike (S) proteins. Biochemical and Biophysical Research Communications 387(2): 326-329, 2009

Co-circulation of human metapneumovirus and SARS-associated coronavirus during a major nosocomial SARS outbreak in Hong Kong. Journal of Clinical Virology 40(4): 333-337, 2007

Profiles of IgG antibodies to nucleocapsid and spike proteins of the SARS-associated coronavirus in SARS patients. Dna and Cell Biology 24(8): 521-527, 2005

Early detection of antibodies against various structural proteins of the SARS-associated coronavirus in SARS patients. Journal of Biomedical Science 11(1): 117-126, 2004

Seroprevalence of antibody to severe acute respiratory syndrome (SARS)-associated coronavirus among health care workers in SARS and non-SARS medical wards. Clinical Infectious Diseases 38(12): E116-E118, 2004

Potential targets for anti-SARS drugs in the structural proteins from SARS related coronavirus. Peptides 25(6): 901-908, 2004

Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. Journal of Pathology 203(2): 622-630, 2004

Derivation of a novel SARS-coronavirus replicon cell line and its application for anti-SARS drug screening. Virology 360(1): 150-158, 2007

Peptide mimicrying between SARS coronavirus spike protein and human proteins reacts with SARS patient serum. Journal of Biomedicine & Biotechnology 2008: 326464-326464, 2008

SARS patients-derived human recombinant antibodies to S and M proteins efficiently neutralize SARS-coronavirus infectivity. Biomedical and Environmental Sciences 18(6): 363-374, 2005